NCT06504485View on ClinicalTrials.gov

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

RecruitingOBSERVATIONAL
Enrollment

192

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatitis D
Interventions
DRUG

Bulevirtide

dose of 2 mg/day subcutaneously

Trial Locations (1)

20122

RECRUITING

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy., Milan

All Listed Sponsors
collaborator

University of Milan

OTHER

collaborator

Parma University Hospital

OTHER

collaborator

University of Rome Tor Vergata

OTHER

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER